A little flattery never hurt, right? Perhaps that’s why Craig Venter, eager to expand Celera’s horizons, says Japan will play an increasingly significant role in what he calls the “golden age of discovery” in proteomics, disease prevention, and medical treatment.
“[Japan] could end up leading the world in terms of the implementation of new ideas in medicine,” Venter says. “We think some of the leading science in genomics is now beginning to take place in Japan. And Celera is very interested in helping to participate in that science.”
Celera demonstrated its commitment to the country by announcing a deal to acquire a minority interest in emerging Japanese firm HuBit Genomix, which focuses on the discovery and association of genes and SNPs for use in therapeutics and diagnostics. The size of the deal was not disclosed.
Japanese representatives at a life science symposium indicated their willingness to consider potential collaborations.
— Sara Harris